브리지바이오파마(주)
DE ˙ XTRA ˙ US10806X1028
€57.05 ↑1.28 (2.30%)
2026-06-05
주가
SecurityDE:2CL / BridgeBio Pharma, Inc.
InstitutionRockefeller Capital Management L.P.
Latest Disclosed Ownership53,621 shares
Latest Disclosed Value $ 3,981,895
Rockefeller Capital Management L.P. reports 39.53% increase in ownership of 2CL / BridgeBio Pharma, Inc.

On May 14, 2026 - Rockefeller Capital Management L.P. filed a 13F-HR form disclosing ownership of 53,621 shares of BridgeBio Pharma, Inc. (DE:2CL) valued at $3,369,544 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on March 16, 2026 disclosing 38,429 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 39.53% during the quarter. The current value of the position is $3,059,078 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 53,621 15,192 39.53 3,982 35.45 0.0071
2026-03-16 2025-12-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 38,429 25,169 189.81 2,939 327.18 0.0053
2026-02-14 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 38,429 25,169 2,939 0.0053
2025-11-14 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 13,260 -25,506 -65.79 689 -58.88 0.0013
2025-08-14 2025-06-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 38,766 21,531 124.93 1,674 181.18 0.0037
2025-08-08 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 38,766 21,531 1,674 0.0021
2025-05-14 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 17,235 -24,054 -58.26 596 -47.44 0.0015
2025-02-13 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 41,289 30 0.07 1,133 7.81 0.0029
2024-11-14 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 41,259 4,317 11.69 1,050 12.30 0.0028
2024-08-12 2024-06-30 13F BRIDGEBIO PHARMA COM 10806X102 36,942 -4,070 -9.92 936 -26.26 0.0027
2024-05-14 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 41,012 -480 -1.16 1,268 -24.30 0.0037
2024-02-14 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 41,492 -700 -1.66 1,675 50.63 0.0056
2023-11-14 2023-09-30 13F BRIDGEBIO PHARMA COM 10806X102 42,192 -16,278 -27.84 1,113 10.65 0.0043
2023-08-14 2023-06-30 13F BRIDGEBIO PHARMA COM 10806X102 58,470 9,268 18.84 1,006 0.0039
2023-05-16 2023-03-31 13F BRIDGEBIO PHARMA COM 10806X102 49,202 3,885 8.57 1 -100.00 0.0035
2023-03-06 2022-12-31 13F BRIDGEBIO PHARMA COM 10806X102 45,317 -5,046 -10.02 345 -31.00 0.0017
2022-11-02 2022-09-30 13F BRIDGEBIO PHARMA COM 10806X102 50,363 -16,476 -24.65 500 -17.49 0.0026
2022-08-12 2022-06-30 13F BRIDGEBIO PHARMA COM 10806X102 66,839 -23,449 -25.97 606 -33.77 0.0032
2022-05-13 2022-03-31 13F BRIDGEBIO PHARMA COM 10806X102 90,288 -1,018,945 -91.86 915 -95.05 0.0044
2022-02-14 2021-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,109,233 272,319 32.54 18,500 -52.83 0.0863
2021-11-12 2021-09-30 13F BRIDGEBIO PHARMA COM 10806X102 836,914 4,830 0.58 39,224 -22.67 0.2061
2021-08-10 2021-06-30 13F BRIDGEBIO PHARMA COM 10806X102 832,084 12,452 1.52 50,722 0.46 0.2857
2021-05-11 2021-03-31 13F BRIDGEBIO PHARMA COM 10806X102 819,632 42,601 5.48 50,488 -8.62 0.3416
2021-02-12 2020-12-31 13F BRIDGEBIO PHARMA COM 10806X102 777,031 777,031 55,253 0.4185
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.